EANS-News: AGENNIX AG Successfully Completes Rights Offering in the Amount of Approximately Euro 27.5 Million

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Capital measures

Planegg/Munich (Germany), December 8, 2011 (euro adhoc) - Company raises
approximately Euro 11.3 million in cash and Euro 16.2 million from the
conversion to equity of an existing loan plus interest

Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4)
today announced that the Company has successfully completed its rights offering
in which shareholders subscribed to all of the offered 9,319,504 new no-par
value bearer shares by the end of the subscription period on December 6, 2011. 
In this transaction, Agennix raised approximately Euro 11.3 million from
subscriptions against cash and approximately Euro 16.2 million from the
conversion to equity of an existing loan plus interest. The subscription price
was Euro 2.95 per share, an approximately 4% discount to the XETRA closing price
of Euro 3.06 per Agennix AG share on the Frankfurt Stock Exchange on November
16, 2011, the date of the announcement of the rights offering. The Management
Board, with the approval of the Supervisory Board, has therefore resolved to
increase the Company's share capital from Euro 41,937,776 to Euro 51,257,280 by
issuing 9,319,504 new shares.

Torsten Hombeck, Ph.D., Chief Financial Officer and Spokesperson of the
Management Board, said: "We are very pleased to have been able to successfully
complete this financing, especially in such a challenging market environment,
and are very grateful for the strong support of dievini, our major shareholder.
We now believe that we have sufficient cash to fund ongoing operations into
2013, strengthening our financial position post our upcoming major data

Dr. Hombeck continued: "The year 2012 will be an exciting one for Agennix.  We
expect to see top-line results from the talactoferrin Phase III FORTIS-M trial
in non-small cell lung cancer in the second quarter of 2012, and, should the
results so warrant, would plan to then file for regulatory approval.  We also
expect to see top-line results from the Phase II part of the talactoferrin OASIS
trial in severe sepsis in the second quarter of 2012 and hope to then initiate
the Phase III part of that trial."

The capital increase was a mixed capital increase of cash and contribution in
kind.  The contribution in kind involved the contribution by the Company's major
shareholder, dievini Hopp BioTech holding GmbH & Co. KG (dievini), of the Euro
15.0 million loan made to Agennix in July 2010, plus approximately Euro 1.2
million in accrued interest.  As previously agreed, dievini exercised all of its
subscription rights in the rights offering with respect to shares held by it,
which represented the principal amount of the loan plus the accrued interest. As
a result of this transaction, Agennix has no further obligations regarding this
loan.   In addition, dievini participated in the oversubscription offering. 
Following the completion of the offering, dievini will hold approximately 65% of
shares outstanding in Agennix.

The entry of the capital increase in the commercial register is expected to
occur on or around December 9, 2011. The new shares are expected to begin
trading in the regulated market in the Prime Standard of the Frankfurt Stock
Exchange on or around December 14, 2011 under the existing stock identification
number AGX/ISIN DE000A1A6XX4. 

Kempen & Co N.V. served as the sole global coordinator for the transaction.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer and in a Phase II/III trial in severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase inhibitor in
Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic
foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company
has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix Web site at

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG, including
statements about the Company's future cash position. Such statements are based
on current expectations and are subject to risks and uncertainties, many of
which are beyond our control, that could cause future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking statements
contained in this press release. Forward-looking statements speak only as of the
date on which they are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available in the

This press release is not for distribution, directly or indirectly, in or into
the United States (including its territories and possessions, any State of the
United States and the District of Columbia). These materials do not constitute
or form a part of any offer or solicitation to purchase or subscribe for
securities in the United States of America. The shares in Agennix AG (the
"Shares") mentioned herein may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended (the "Securities Act"). 

The Shares have not been, and will not be, registered under the Securities Act
and will not be offered or sold in the United States, except on the basis of
applicable exemptions from registration. There will be no public offering of
securities in the United States or elsewhere.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 		
Phone: +49 (0)89 8565 2693
In the U.S.: Laurie Doyle		
Senior Director, Investor Relations & Corporate Communications		
Phone: +1 609 524 5884
Additional media contact for Europe:	
MC Services AG	
Raimund Gabriel	
Phone: +49 (0) 89 210 228 0
Additional investor contact for Europe:	
Trout International LLC	
Lauren Williams, Vice President	
Phone: +44 207 936 9325

end of announcement                               euro adhoc 

company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: AGENNIX AG

Das könnte Sie auch interessieren: